Pet dander and perennial allergic rhinitis: Therapeutic options

Allergy and Asthma Proceedings

Volumn 30, Issue 6, 2009, Pages 573-583

  Wallace, Dana V ^a  

^a NOVA SOUTHEASTERN UNIVERSITY   (United States)

Author keywords

Allergen immunotherapy; Allergic conjunctivitis; Allergic rhinitis; Can f 1; Efficacy; Environmental control; Episodic allergic rhinitis; Fel d 1; Pet allergy; Pharmacotherapy; Safety

Indexed keywords

ALLERGEN; ANTIHISTAMINIC AGENT; CORTICOSTEROID; CROMOGLYCATE DISODIUM; DECONGESTIVE AGENT; ENDOTOXIN; IMMUNOMODULATING AGENT; IPRATROPIUM BROMIDE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; VASOCONSTRICTOR AGENT;

ALLERGIC RHINITIS; ALLERGY; ANIMAL ALLERGY; CAT; CLINICAL TRIAL; CONFERENCE PAPER; DANDER; DIAGNOSTIC TEST; DOG; ENVIRONMENT; EVIDENCE BASED PRACTICE; EXPOSURE; HEALTH CARE PLANNING; HOME; HOUSEHOLD; HUMAN; IMMUNOTHERAPY; MEDICAL RESEARCH; NONHUMAN; PERENNIAL RHINITIS; PET ANIMAL; PRICK TEST; QUESTIONNAIRE; RHINOCONJUNCTIVITIS; UNITED STATES;

ADRENAL CORTEX HORMONES; ALLERGENS; ANIMALS; ANIMALS, DOMESTIC; CATS; DESENSITIZATION, IMMUNOLOGIC; DOGS; ENVIRONMENT, CONTROLLED; EVIDENCE-BASED MEDICINE; GLYCOPROTEINS; HISTAMINE ANTAGONISTS; HUMANS; LEUKOTRIENE ANTAGONISTS; PRACTICE GUIDELINES AS TOPIC; RHINITIS, ALLERGIC, PERENNIAL; SERUM ALBUMIN; UNITED STATES;

EID: 73649092731     PISSN: 10885412     EISSN: 15396304     Source Type: Journal    
DOI: 10.2500/aap.2009.30.3286     Document Type: Conference Paper

References (83)

1. Wallace DV, Dykewicz M, Bernstein D, et al. The diagnosis and management of rhinitis: An updated practice parameter. J Allergy Clin Immunol 122(suppl 2):S1-S84, 2008.
2. Nathan RA. The burden of allergic rhinitis. Allergy Asthma Proc 28:3-9, 2007.
3. Nathan RA, Meltzer EO, Derebery J, et al. The prevalence of nasal symptoms attributed to allergies in the United States: Findings from the burden of rhinitis in an America survey. Allergy Asthma Proc 29:600-608, 2008.
4. Blaiss MS. Pediatric allergic rhinitis: Physical and mental complications. Allergy Asthma Proc 29:1-6, 2008.
5. American Veterinary Medical (AVM) Association. U.S. Pet Ownership & Demographics Sourcebook. 2007.
6. de Groot H, Goei KG, van Swieten P, et al. Affinity purification of a major and a minor allergen from dog extract: Serologic activity of affinity-purified Can f I and of Can f I-depleted extract. J Allergy Clin Immunol 87:1056-1065, 1991.
7. Craig TJ, King TS, Lemanske RF Jr, et al. Aeroallergen sensitization correlates with PC(20) and exhaled nitric oxide in subjects with mild-to-moderate asthma. J Allergy Clin Immunol 121:671-677, 2008.
8. Liccardi G, Barber D, Russo M, et al. Human hair: An unexpected source of cat allergen exposure. Int Arch Allergy Immunol 137:141-144, 2005.
9. Persky V, Coover L, Hernandez E, et al. Chicago community-based asthma intervention trial: Feasibility of delivering peer education in an inner-city population. Chest 116(suppl 1):216S-223S, 1999.
10. Eggleston PA. Improving indoor environments: Reducing allergen exposures. J Allergy Clin Immunol 116:122-126, 2005.
11. Ingram JM, Sporik R, Rose G, et al. Quantitative assessment of exposure to dog (Can f 1) and cat (Fel d 1) allergens: Relation to sensitization and asthma among children living in Los Alamos, New Mexico. J Allergy Clin Immunol 96:449-456, 1995.
12. Ritz BR, Hoelscher B, Frye C, et al. Allergic sensitization owing to "second-hand" cat exposure in schools. Allergy 57:357-361, 2002.
13. Siebers R, Oldfield K, and Crane J, Child-care center sandpits: A source of cat allergen (Fel d 1). J Allergy Clin Immunol 118:533-534, 2006.
14. Almqvist C, Larsson PH, Egmar AC, et al. School as a risk environment for children allergic to cats and a site for transfer of cat allergen to homes. J Allergy Clin Immunol 103:1012-1017, 1999.
15. De Lucca SD, O'Meara JT, and Tovey ER. Exposure to mite and cat allergens on a range of clothing items at home and the transfer of cat allergen in the workplace. J Allergy Clin Immunol 106:874-879, 2000.
16. Enberg RN, Shamie SM, McCullough J, et al. Ubiquitous presence of cat allergen in cat-free buildings: Probable dispersal from human clothing. Ann Allergy 70:471-474, 1993.
17. Almqvist C, Wickman M, Perfetti L, et al. Worsening of asthma in children allergic to cats, after indirect exposure to cat at school. Am J Respir Crit Care Med 163:694-698, 2001.
18. Bollinger ME, Eggleston PA, Flanagan E, et al. Cat antigen in homes with and without cats may induce allergic symptoms. J Allergy Clin Immunol 97:907-914, 1996.
19. Carayol N, Birnbaum J, Magnan A, et al. Fel d 1 production in the cat skin varies according to anatomical sites. Allergy 55: 570-557 2000.
20. Adedoyin J, Gronlund H, Oman H, et al. Cat IgA, representative of new carbohydrate cross-reactive allergens. J Allergy Clin Immunol 119:640-664 2007.
21. Ramadour M, Birnbaum J, Magalon C, et al. Cat sex differences in major allergen production (Fel d 1). J Allergy Clin Immunol 101:282-228 1998
22. Dabrowski AJ, Van der Brempt X, Soler M, et al. Cat skin as an important source of Fel d I allergen. J Allergy Clin Immunol 86:462-446 1990
23. Saarelainen S, Taivainen A, Rytkonen-Nissinen M, et al. Assessment of recombinant dog allergens Can f 1 and Can f 2 for the diagnosis of dog allergy. Clin Exp Allergy 34:1576-1515, 2004.
24. Engel E, Richter K, Obermeyer G, et al. Immunological and biological properties of Bet v 4, a novel birch pollen allergen with two EF-hand calcium-binding domains. J Biol Chem 272: 28630-28537, 1997.
25. Swoboda I, De Weerd N, Bhalla PL, et al. Mutants of the major ryegrass pollen allergen, Lol p 5, with reduced IgE-binding capacity: Candidates for grass pollen-specific immunotherapy. Eur J Immunol 32:270-280, 2002.
26. Okada T, Swoboda I, Bhalla PL, et al. Engineering of hypoallergenic mutants of the Brassica pollen allergen, Bra r 1, for immunotherapy. FEBS Lett 434:255-260, 1998.
27. Bannon GA, Cockrell G, Connaughton C, et al. Engineering, characterization and in vitro efficacy of the major peanut allergens for use in immunotherapy. Int Arch Allergy Immunol 124:70-72, 2001.
28. Kamata Y, Miyanomae A, Nakayama E, et al. Characterization of dog allergens Can f 1 and Can f 2. 1. Preparation of their recombinant proteins and antibodies. Int Arch Allergy Immunol 142:291-300, 2007.
29. Ramadour M, Guetat M, Guetat J, et al. Dog factor differences in Can f 1 allergen production. Allergy 60:1060-1064, 2005.
30. Mattsson L, Lundgren T, Everberg H, et al. Prostatic kallikrein: A new major dog allergen. J Allergy Clin Immunol 123:362-368, 2009.
31. Basagana M, Bartolome B, Pastor C, et al. Allergy to human seminal fluid: Cross-reactivity with dog dander. J Allergy Clin Immunol 121:233-239, 2008.
32. Weidinger S, Mayerhofer A, Raemsch R, et al. Prostate-specific antigen as allergen in human seminal plasma allergy. J Allergy Clin Immunol 117:213-215, 2006.
33. Reininger R, Varga EM, Zach M, et al. Detection of an allergen in dog dander that cross-reacts with the major cat allergen, Fel d 1. Clin Exp Allergy 37:116-1124, 2007.
34. Platts-Mills JA, Custis NJ, Woodfolk JA, et al. Airborne endotoxin in homes with domestic animals: Implications for cat-specific tolerance. J Allergy Clin Immunol 116:384-389, 2005.
35. Campo P, Kalra HK, Levin L, et al. Influence of dog ownership and high endotoxin on wheezing and atopy during infancy. J Allergy Clin Immunol 118:1271-1278, 2006.
36. Svanes C, Heinrich J, Jarvis D, et al. Pet-keeping in childhood and adult asthma and hay fever: European community respiratory health survey. J Allergy Clin Immunol 112:289-300, 2003.
37. Gern JE, Reardon CL, Hoffjan S, et al. Effects of dog ownership and genotype on immune development and atopy in infancy. J Allergy Clin Immunol 113:307-314, 2004.
38. Erwin EA, Wickens K, Custis NJ, et al. Cat and dust mite sensitivity and tolerance in relation to wheezing among children raised with high exposure to both allergens. J Allergy Clin Immunol 115:74-79, 2005.
39. Gendo K, and Larson EB, Evidence-based diagnostic strategies for evaluating suspected allergic rhinitis. Ann Intern Med 140: 278-289, 2004.
40. Corren J, Fish H, and Gumarange J. Nasal response to natural cat allergen exposure is significantly greater in patients with rhinitis and asthma than in patients with rhinitis alone. J Allergy Clin Immunol 115:202-203, 2005.
41. Karlsson AS, Andersson B, Renstrom A, et al. Airborne cat allergen reduction in classrooms that use special school clothing or ban pet ownership. J Allergy Clin Immunol 113:1172-1177, 2004.
42. Bernstein L, Li J, Bernstein D, et al. Allergy diagnostic testing: An updated practice parameter. Ann Allergy 100:S1-S148, 2008.
43. Wood RA, Phipatanakul W, Hamilton RG, et al. A comparison of skin prick tests, intradermal skin tests, and RASTs in the diagnosis of cat allergy. J Allergy Clin Immunol 103:773-779, 1999.
44. Moira CY, Ferguson A, Dimich-Ward H, et al. Effectiveness of and compliance to intervention measures in reducing house dust and cat allergen levels. Ann Allergy Asthma Immunol 88:52-58, 2002.
45. The Humane Society. Allergies to pets. Available online at www.hsus.org/pets/pet-care/allergies-to-pets/; last accessed October 2009.
46. Wood RA, Chapman MD, Adkinson NF Jr, et al. The effect of cat removal on allergen content in household-dust samples. J Allergy Clin Immunol 83:730-734, 1989.
47. Kilburn S, Lasserson TJ, and McKean M. Pet allergen control measures for allergic asthma in children and adults. Cochrane Database Syst Rev 1:CD002989, 2003.
48. de Blay F, Chapman MD, and Platts-Mills TA. Airborne cat allergen (Fel d I). Environmental control with the cat in situ. Am Rev Respir Dis 143:1334-1339, 1991.
49. Berge M, Munir AK, and Dreborg S. Concentrations of cat (Fel d1), dog (Can f1) and mite (Der f1 and Der p1) allergens in the clothing and school environment of Swedish schoolchildren with and without pets at home. Pediatr Allergy Immunol 9:25-30, 1998.
50. Avner DB, Perzanowski MS, Platts-Mills TA, et al. Evaluation of different techniques for washing cats: Quantitation of allergen removed from the cat and the effect on airborne Fel d 1. J Allergy Clin Immunol 100:307-312, 1997.
51. Hodson T, Custovic A, Simpson A, et al. Washing the dog reduces dog allergen levels, but the dog needs to be washed twice a week. J Allergy Clin Immunol 103:581-585, 1999.
52. Nageotte C, Park M, Havstad S, et al. Duration of airborne Fel d 1 reduction after cat washing. J Allergy Clin Immunol 118:521-522, 2006.
53. Munir AK, Einarsson R, and Dreborg SK. Indirect contact with pets can confound the effect of cleaning procedures for reduction of animal allergen levels in house dust. Pediatr Allergy Immunol 5:32-39, 1994.
54. Gore RB, Durrell B, Bishop S, et al. High-efficiency particulate arrest-filter vacuum cleaners increase personal cat allergen exposure in homes with cats. J Allergy Clin Immunol 111:784-787, 2003.
55. Gore RB, Bishop S, Durrell B, et al. Air filtration units in homes with cats: Can they reduce personal exposure to cat allergen? Clin Exp Allergy 33:765-769, 2003.
56. Wood RA, Johnson EF, Van Natta ML, et al. A placebo-controlled trial of a HEPA air cleaner in the treatment of cat allergy. Am J Respir Crit Care Med 158:115-120, 1998.
57. van der Heide S, Kauffman HF, Dubois AE, et al. Allergen reduction measures in houses of allergic asthmatic patients: Effects of air-cleaners and allergen-impermeable mattress covers. Eur Respir J 10:1217-1223, 1997.
58. Klucka CV, Ownby DR, Green J, et al. Cat shedding of Fel d I is not reduced by washings, Allerpet-C spray, or acepromazine. J Allergy Clin Immunol 95:1164-1171, 1995.
59. Carswell F, Oliver J, and Weeks J. Do mite avoidance measures affect mite and cat airborne allergens? Clin Exp Allergy 29:193-200, 1999.
60. Choi SY, Lee IY, Sohn JH, et al. Optimal conditions for the removal of house dust mite, dog dander, and pollen allergens using mechanical laundry. Ann Allergy Asthma Immunol 100:583-588, 2008.
61. Arbes SJ Jr, Sever M, Archer J, et al. Abatement of cockroach allergen (Bla g 1) in low-income, urban housing: A randomized controlled trial. J Allergy Clin Immunol 112:339-345, 2003.
62. Dykewicz MS, Fineman S, Skoner DP, et al. Diagnosis and management of rhinitis: Complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology. American Academy of Allergy, Asthma, and Immunology. Ann Allergy Asthma Immunol 81:478-518, 1998.
63. Patel P, D'Andrea C, and Sacks HJ. Onset of action of azelastine nasal spray compared with mometasone nasal spray and placebo in subjects with seasonal allergic rhinitis evaluated in an environmental exposure chamber. Am J Rhinol 21:499-503, 2007.
64. Kaszuba SM, Baroody FM, deTineo M, et al. Superiority of an intranasal corticosteroid compared with an oral antihistamine in the as-needed treatment of seasonal allergic rhinitis. Arch Intern Med 161:2581-2587, 2001.
65. Jen A, Baroody F, deTineo M, et al. As-needed use of fluticasone propionate nasal spray reduces symptoms of seasonal allergic rhinitis. J Allergy Clin Immunol 105:732-738, 2000.
66. Dykewicz MS, Kaiser HB, Nathan RA, et al. Fluticasone propionate aqueous nasal spray improves nasal symptoms of seasonal allergic rhinitis when used as needed (prn). Ann Allergy Asthma Immunol 91:44-48, 2003.
67. Fairchild CJ, Meltzer EO, Roland PS, et al. Comprehensive report of the efficacy, safety, quality of life, and work impact of Olopatadine 0.6% and Olopatadine 0.4% treatment in patients with seasonal allergic rhinitis. Allergy Asthma Proc 28:716-723, 2007.
68. Patel D, Garadi R, Brubaker M, et al. Onset and duration of action of nasal sprays in seasonal allergic rhinitis patients: Olopatadine hydrochloride versus mometasone furoate monohydrate. Allergy Asthma Proc 28:592-599, 2007.
69. Kaliner MA, Storms W, Tilles S, et al. Comparison of olopatadine 0.6% nasal spray versus fluticasone propionate 50 mug in the treatment of seasonal allergic rhinitis. Allergy Asthma Proc 30:255-262, 2009.
70. Segall N, Grubbe RE, Levy AL, et al. Pharmacokinetics, safety and tolerability of an oral suspension of fexofenadine for children with allergic rhinitis. Allergy Asthma Proc 29:380-385, 2008.
71. Dubuske LM. Levocetirizine: The latest treatment option for allergic rhinitis and chronic idiopathic urticaria. Allergy Asthma Proc 28:724-734, 2007.
72. Schad CA, and Skoner DP. Antihistamines in the pediatric population: achieving optimal outcomes when treating seasonal allergic rhinitis and chronic urticaria. Allergy Asthma Proc 29:7-13, 2008.
73. Bronsky E, Boggs P, Findlay S, et al. Comparative efficacy and safety of a once-daily loratadine-pseudoephedrine combination versus its components alone and placebo in the management of seasonal allergic rhinitis. J Allergy Clin Immunol 96:139-147, 1995.
74. Bertrand B, Jamart J, Marchal JL, et al. Cetirizine and pseudoephedrine retard alone and in combination in the treatment of perennial allergic rhinitis: A double-blind multicentre study. Rhinology 34:91-96, 1996.
75. Ratner P, Hampel F, Van Bavel J, et al. Combination therapy with azelastine hydrochloride nasal spray is more effective than either agent alone in the treatment of patients with seasonal allergic rhinitis. Ann Allergy 100:74-81, 2008.
76. Cox L, Li J, Nelson HS, et al. Allergen immunotherapy: A practice prameter second update. J Allergy Clin Immunol 120: S25-S85, 2007.
77. Cox L, Li J, Nelson H, et al. Allergen immunotherapy: A practice parameter second update. J Allergy Clin Immunol. In press.
78. Hedlin G, Heilborn H, Lilja G, et al. Long-term follow-up of patients treated with a three-year course of cat or dog immunotherapy. J Allergy Clin Immunol 96:879-885, 1995.
79. Alvarez-Cuesta E, Berges-Gimeno P, Gonzalez-Mancebo E, et al. Sublingual immunotherapy with a standardized cat dander extract: Evaluation of efficacy in a double blind placebo controlled study. Allergy 62:810-817, 2007.
80. Esch RE, Bush RK, Peden D, et al. Sublingual-oral administration of standardized allergenic extracts: Phase 1 safety and dosing results. Ann Allergy Asthma Immunol 100:475-481, 2008.
81. Nelson HS, Oppenheimer J, Vatsia GA, et al. A double-blind, placebo-controlled evaluation of sublingual immunotherapy with standardized cat extract. J Allergy Clin Immunol 92:229-236, 1993.
82. Larche M. Update on the current status of peptide immunotherapy. J Allergy Clin Immunol 119:906-909, 2007.
83. Wallace DV, Dykewicz MS, Bernstein DI, et al. Rhinitis action plan, revised. J Allergy Clin Immunol 122:1237, 2008.